ses • Multiple Sclerosis (MS) • US prevalence of approx. 400,000 patients; Potential market of approx. $1.5.3 billion based on Copaxone, Avonex, & Rebif comparables • ldlopathk Pulmonary Fibrosis (IPF) • US incidence of approx. 20,000-50,CCOcases annually; Global market was valued at $2 billion in